TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33787078

Group type: EXPERIMENTAL
Intervention: ADI-PEG20 plus low-dose cytarabine (LDC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-dose cytarabine (LDC)
Number of subjects: 0
Study: 33787290

Group type: EXPERIMENTAL
Intervention: RISTRA-ACS
Number of subjects: 13192

Group type: EXPERIMENTAL
Intervention: HEART pathway
Number of subjects: 13192

Group type: COMPARATOR
Intervention: HEART score, Emergency Department Assessment of Chest Pain Score Accelerated Diagnostic Protocol, troponin-only strategies, unstructured physician gestalt
Number of subjects: 13192
Study: 33787401

Group type: EXPERIMENTAL
Intervention: Super-selective intra-arterial indocyanine green (ICG) administration (5 mL bolus at .125 mg/mL)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Super-selective intra-arterial indocyanine green (ICG) administration
Number of subjects: 8
Study: 33787530

Group type: EXPERIMENTAL
Intervention: Aerobic exercise training after 14 days of immobilization
Number of subjects: 1

Group type: COMPARATOR
Intervention: Immobilization for 14 days
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Functional assessment during rest and submaximal exercise
Number of subjects: 1
Study: 33787565

Group type: EXPERIMENTAL
Intervention: Routine complete blood count (CBC) on the first postoperative day
Number of subjects: 570
Study: 33788415

Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) atezolizumab coformulated with recombinant human hyaluronidase
Number of subjects: 0

Group type: COMPARATOR
Intervention: Intravenous (IV) atezolizumab
Number of subjects: 0
Study: 33788611

Group type: EXPERIMENTAL
Intervention: Integrative Medicine Interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pain Medication
Number of subjects: 0
Study: 33788646

Group type: EXPERIMENTAL
Intervention: Oncoplastic breast surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional breast conserving surgery
Number of subjects: 0
Study: 33789265

Group type: EXPERIMENTAL
Intervention: Endexo dialyzer
Number of subjects: 41

Group type: COMPARATOR
Intervention: Optiflux dialyzer
Number of subjects: 41
Study: 33789592

Group type: EXPERIMENTAL
Intervention: Dabigatran 150 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 0
Study: 33789635

Group type: EXPERIMENTAL
Intervention: Integration of massive and heterogeneous data concerning the patient's environment, personal and familial history, clinical and biological data, imaging, histological results, and microbiota analysis.
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Creation of a clinico-biological database prospectively by collecting epidemiological, socio-economic, clinical, biological, pathological, multi-omic data.
Number of subjects: 300
Study: 33789643

Group type: EXPERIMENTAL
Intervention: Non-restorative cavity control (NRCC) through cavity enlargement using metallic sandpaper
Number of subjects: 148

Group type: COMPARATOR
Intervention: Resin composite restorations (RCR)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: NRCC
Number of subjects: 148

Group type: COMPARATOR
Intervention: RCR
Number of subjects: 148
Study: 33789701

Group type: EXPERIMENTAL
Intervention: RV fast global longitudinal strain (GLS) in PAH patients
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: RV fast global longitudinal strain (GLS) in rTOF patients
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: RV fast global longitudinal strain (GLS) in rTOF and PAH patients
Number of subjects: 150
Study: 33789723

Group type: EXPERIMENTAL
Intervention: Left Ventricular Assist Device (LVAD) as destination therapy
Number of subjects: 16
Study: 33789739

Group type: EXPERIMENTAL
Intervention: PAIN
Number of subjects: 76

Group type: COMPARATOR
Intervention: PubMed
Number of subjects: 76
Study: 33789756

Group type: EXPERIMENTAL
Intervention: PFO-closure in high-risk PFO patients ≤60 years (n=103)
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: PFO-closure in high-risk PFO patients >60 years (n=43)
Number of subjects: 236
Study: 33789855

Group type: EXPERIMENTAL
Intervention: Early diagnostic assessments (EDA) using echocardiograms performed in the third week of age and at 32 weeks PMA.
Number of subjects: 350

Group type: EXPERIMENTAL
Intervention: Predefined echocardiographic markers including pulmonary artery acceleration time and tricuspid annular plane systolic excursion.
Number of subjects: 350

Group type: COMPARATOR
Intervention: Standard diagnostic assessment (SDA) for cPH at 36 weeks PMA.
Number of subjects: 350
Study: 33790041

Group type: EXPERIMENTAL
Intervention: Increased physical activity
Number of subjects: 173

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 173
Study: 33790560

Group type: EXPERIMENTAL
Intervention: Group A (with insomnia, N=78)
Number of subjects: 299

Group type: COMPARATOR
Intervention: Group B (without insomnia, N=221)
Number of subjects: 299
Study: 33790605

Group type: EXPERIMENTAL
Intervention: Visceral Fat Area (VFA) measurement
Number of subjects: 1017

Group type: EXPERIMENTAL
Intervention: Optimal cut-off value of VFA
Number of subjects: 1017
Study: 33790783

Group type: EXPERIMENTAL
Intervention: TangWang Prescription
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 33790833

Group type: EXPERIMENTAL
Intervention: Two exergame and two regular training sessions/week
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: One exergame and one regular training session/week
Number of subjects: 63

Group type: COMPARATOR
Intervention: Two regular training sessions/week
Number of subjects: 63

Group type: COMPARATOR
Intervention: One regular training session/week
Number of subjects: 63
Study: 33790870

Group type: EXPERIMENTAL
Intervention: S-osteoglycin levels in T1D patients
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: S-osteoglycin levels in T2D patients
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Associations of S-osteoglycin with age, gender, microvascular complications, HbA1c, or plasma glucose in T1D patients
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Associations of S-osteoglycin with age, gender, microvascular complications, HbA1c, or plasma glucose in T2D patients
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Associations of S-osteoglycin with bone turnover markers (CTX, P1NP, OC, sclerostin, OPG, RANKL) in T1D patients
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Associations of S-osteoglycin with bone turnover markers (CTX, P1NP, OC, sclerostin, OPG, RANKL) in T2D patients
Number of subjects: 190
Study: 33790901

Group type: EXPERIMENTAL
Intervention: Pre-antivenom model
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Post-antivenom model
Number of subjects: 28
Study: 33791018

Group type: EXPERIMENTAL
Intervention: Group PDN (19 patients)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Group NDN (20 patients)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Healthy controls (13 participants)
Number of subjects: 39
Study: 33791217

Group type: EXPERIMENTAL
Intervention: HID-PBSCT using G-PB grafts
Number of subjects: 67

Group type: COMPARATOR
Intervention: HID HSCT using the combination of G-BM and G-PB grafts
Number of subjects: 67
Study: 33791343

Group type: EXPERIMENTAL
Intervention: Cocoa Flavanols
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33791349

Group type: EXPERIMENTAL
Intervention: Routine oxygen therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no routine oxygen therapy)
Number of subjects: 0
Study: 33791897

Group type: EXPERIMENTAL
Intervention: Brachial plexus blockade (BPB)
Number of subjects: 14
Study: 33791920

Group type: EXPERIMENTAL
Intervention: Pmsa (computerized algorithm)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Pms-Insp (interventional method)
Number of subjects: 18
Study: 33792221

Group type: EXPERIMENTAL
Intervention: CAR-T therapies targeting B-cell maturation antigen (BCMA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CAR-T therapies targeting other antigens (SLAMF7 and CD44v6)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Current autologous CAR-T therapies
Number of subjects: 0
Study: 33792222

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Number of subjects: 0
Study: 33792553

Group type: EXPERIMENTAL
Intervention: Apple Watch Series 4 paired with iPhone and RIFitTest app
Number of subjects: 25
Study: 33792627

Group type: EXPERIMENTAL
Intervention: Caloric and nutrient restriction intervention
Number of subjects: 40

Group type: COMPARATOR
Intervention: Historical control
Number of subjects: 40
Study: 33792630

Group type: EXPERIMENTAL
Intervention: Venetoclax and 10-day decitabine
Number of subjects: 97
Study: 33792661

Group type: EXPERIMENTAL
Intervention: Composite cardiac magnetic resonance (CMR)-based risk score
Number of subjects: 1008

Group type: EXPERIMENTAL
Intervention: Composite clinical and CMR-based risk score
Number of subjects: 1008

Group type: COMPARATOR
Intervention: Standard-of-care (SOC) evaluation
Number of subjects: 1008
Study: 33792960

Group type: EXPERIMENTAL
Intervention: TS-HDS/FGFR3 antibodies
Number of subjects: 322
Study: 33793363

Group type: EXPERIMENTAL
Intervention: ACL reconstruction (ACLR)
Number of subjects: 133
Study: 33793651

Group type: EXPERIMENTAL
Intervention: MRI-based proton density fat fraction (PDFF) using LMS-IDEAL
Number of subjects: 581

Group type: COMPARATOR
Intervention: Ultrasound-derived controlled attenuation parameter (CAP)
Number of subjects: 581
Study: 33794206

Group type: EXPERIMENTAL
Intervention: Alpelisib 300 mg/day plus fulvestrant 500 mg intramuscularly on day 1 of each 28-day cycle and on day 15 of cycle 1
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Alpelisib plus fulvestrant
Number of subjects: 127
Study: 33794207

Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy (weekly intravenous cisplatin 40 mg/m2) and MRI-based adaptive brachytherapy (IGABT)
Number of subjects: 1341
Study: 33794315

Group type: EXPERIMENTAL
Intervention: Higher C-reactive protein (CRP) polygenic risk score (PRS)
Number of subjects: 112171

Group type: EXPERIMENTAL
Intervention: Higher C-reactive protein (CRP) PRS
Number of subjects: 112171

Group type: EXPERIMENTAL
Intervention: Higher TNF-α PRS
Number of subjects: 112171

Group type: EXPERIMENTAL
Intervention: Higher BMI PRS
Number of subjects: 112171
Study: 33794440

Group type: EXPERIMENTAL
Intervention: Pembrolizumab plus eribulin
Number of subjects: 44
Study: 33794531

Group type: EXPERIMENTAL
Intervention: Current smoking
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: History of allergy
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: Respiratory allergy
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: Age 60 years or more
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: Hospitalization
Number of subjects: 376
Study: 33794793

Group type: EXPERIMENTAL
Intervention: DACOLT study participants
Number of subjects: 600

Group type: COMPARATOR
Intervention: Copenhagen General Population Study (CGPS) and Copenhagen City Heart Study (CCHS) controls
Number of subjects: 600
Study: 33794832

Group type: EXPERIMENTAL
Intervention: SensiumVitals™ patch measuring temperature, heart & respiratory rates applied on arrival for the duration of stay.
Number of subjects: 14
Study: 33794842

Group type: EXPERIMENTAL
Intervention: Insomniac patients (ISI > 7)
Number of subjects: 28
Study: 33794948

Group type: EXPERIMENTAL
Intervention: FES + VFBT (functional electrical stimulation with visual feedback balance training)
Number of subjects: 5
Study: 33794977

Group type: EXPERIMENTAL
Intervention: 12 months exercise intervention
Number of subjects: 137

Group type: COMPARATOR
Intervention: Conventional follow-up
Number of subjects: 137
Study: 33795193

Group type: EXPERIMENTAL
Intervention: Gemcitabine for high hENT1 (≥50%) group
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil plus folinic acid (5-FU/FA) for low hENT1 (<50%) group
Number of subjects: 44

Group type: COMPARATOR
Intervention: Control group (hENT1-independent adjuvant chemotherapy)
Number of subjects: 44
Study: 33795208

Group type: EXPERIMENTAL
Intervention: Tagraxofusp and Azacitidine
Number of subjects: 0
Study: 33795869

Group type: EXPERIMENTAL
Intervention: Intravitreal sepofarsen injection
Number of subjects: 1
Study: 33796143

Group type: EXPERIMENTAL
Intervention: Diroximel fumarate (DRF)
Number of subjects: 504

Group type: COMPARATOR
Intervention: Dimethyl fumarate (DMF)
Number of subjects: 504
Study: 33796147

Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 40
Study: 33796237

Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ofatumumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chlorambucil
Number of subjects: 0
Study: 33796451

Group type: EXPERIMENTAL
Intervention: Neratinib
Number of subjects: 25
Study: 33796452

Group type: EXPERIMENTAL
Intervention: CPS + EG
Number of subjects: 1077

Group type: EXPERIMENTAL
Intervention: Neo-Bioscore
Number of subjects: 1077

Group type: EXPERIMENTAL
Intervention: Modified Neo-Bioscore
Number of subjects: 1077

Group type: COMPARATOR
Intervention: Trastuzumab therapy
Number of subjects: 1077

Group type: COMPARATOR
Intervention: HER2-negative patients
Number of subjects: 1077
Study: 33796490

Group type: EXPERIMENTAL
Intervention: Surveillance of Acute SARS-CoV-2 Infections
Number of subjects: 0
Study: 33797395

Group type: EXPERIMENTAL
Intervention: Thought Spot mental health app
Number of subjects: 0
Study: 33797852

Group type: EXPERIMENTAL
Intervention: Periodontitis patients (n=50)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Non-periodontitis individuals (n=50)
Number of subjects: 100
Study: 33798033

Group type: EXPERIMENTAL
Intervention: Telehealth behavior change intervention for promoting physical activity and fruit and vegetable consumption
Number of subjects: 0
Study: 33798209

Group type: EXPERIMENTAL
Intervention: Metabolite profiling (measured 408 metabolites using mass spectrometry)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (survivors who did not require transfer to the ICU)
Number of subjects: 96
Study: 33798399

Group type: EXPERIMENTAL
Intervention: Complex Decongestive Physiotherapy
Number of subjects: 0
Study: 33798541

Group type: EXPERIMENTAL
Intervention: Probe-based confocal laser endomicroscopy (pCLE)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Probe-based confocal laser endomicroscopy (pCLE) at bifurcation
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Probe-based confocal laser endomicroscopy (pCLE) at right hepatic duct
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Probe-based confocal laser endomicroscopy (pCLE) at common bile duct
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Probe-based confocal laser endomicroscopy (pCLE) at left hepatic duct
Number of subjects: 59
Study: 33798613

Group type: EXPERIMENTAL
Intervention: Doxorubicin and ifosfamide for three neoadjuvant cycles plus concomitant hypofractionated radiotherapy (25 Gy in 5 fractions)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Doxorubicin and ifosfamide plus hypofractionated RT
Number of subjects: 18
Study: 33799685

Group type: EXPERIMENTAL
Intervention: Posttransplant cyclophosphamide (PTCy) 50 mg/kg on days +3 and +4 combined with tacrolimus/mycophenolate mofetil (T/MMF) starting day +5
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Posttransplant cyclophosphamide (PTCy) 50 mg/kg combined with T/MMF
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Posttransplant cyclophosphamide (PTCy) + T/MMF
Number of subjects: 85
Study: 33799966

Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cell-derived exosomes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mechanical ventilators
Number of subjects: 0
Study: 33800872

Group type: EXPERIMENTAL
Intervention: Salvage radiation therapy (SRT) at 70 Gy in 35 fractions + locoregional deep hyperthermia (HT) (7-10 sessions)
Number of subjects: 52
Study: 33800969

Group type: EXPERIMENTAL
Intervention: High Periodontal Index (HPI) group (PI > 22)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Low Periodontal Index (LPI) group (PI < 22)
Number of subjects: 52
Study: 33801399

Group type: EXPERIMENTAL
Intervention: Trabectedin, administered every three weeks, median of four cycles (range: 1-40), mostly as a second-line treatment (~60% of patients)
Number of subjects: 512
Study: 33801995

Group type: EXPERIMENTAL
Intervention: Macronutrient intakes in PCOS girls
Number of subjects: 59
Study: 33802089

Group type: EXPERIMENTAL
Intervention: Imatinib mesylate + Bevacizumab
Number of subjects: 48

Group type: COMPARATOR
Intervention: Imatinib mesylate
Number of subjects: 48

Group type: COMPARATOR
Intervention: Bevacizumab
Number of subjects: 48
Study: 33803049

Group type: EXPERIMENTAL
Intervention: solid ASD of efavirenz 50 mg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: dissolved ASD of efavirenz 50 mg
Number of subjects: 16

Group type: COMPARATOR
Intervention: molecular solution of efavirenz 3 mg (non-ASD)
Number of subjects: 16
Study: 33803366

Group type: EXPERIMENTAL
Intervention: Directed to Emergency Department (ED)
Number of subjects: 1081

Group type: COMPARATOR
Intervention: Directed to ED but not admitted to ICU
Number of subjects: 1081

Group type: COMPARATOR
Intervention: Admitted to ICU within 7 days
Number of subjects: 1081

Group type: COMPARATOR
Intervention: Transported by Mobile Intensive Care Unit (MICU) directly to ICU
Number of subjects: 1081
Study: 33804500

Group type: EXPERIMENTAL
Intervention: Transmission Reduction Intervention Project (TRIP)
Number of subjects: 292
Study: 33804657

Group type: EXPERIMENTAL
Intervention: Thermographic imaging after local cooling of the hands for 1 min in water of 10°C
Number of subjects: 22

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 22
Study: 33804976

Group type: EXPERIMENTAL
Intervention: Calcium-containing Eggshell Powder (ESP) supplementation, 2.4 g daily for 6 months
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Calcium-containing Eggshell Powder (ESP) supplementation
Number of subjects: 82
Study: 33804999

Group type: EXPERIMENTAL
Intervention: Probiotic supplementation
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 200
Study: 33805367

Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy (SLNB)
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Targeted axillary dissection (TAD)
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Full axillary lymph node dissection (ALND)
Number of subjects: 3000
Study: 33805731

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy combined with regional hyperthermia (RHT) including radiotherapy with concurrent 5-Fluorouracil (5-FU)/Capecitabine and Oxaliplatin.
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemoradiotherapy combined with regional hyperthermia (RHT).
Number of subjects: 111
Study: 33805793

Group type: EXPERIMENTAL
Intervention: Cabazitaxel 20 mg/m²
Number of subjects: 0
Study: 33806653

Group type: EXPERIMENTAL
Intervention: Cognitive functioning assessment in juvenile athletes who were donor twins
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive functioning assessment in juvenile athletes who were recipient twins
Number of subjects: 0
Study: 33807097

Group type: EXPERIMENTAL
Intervention: Bivalent oral vaccine against enteric fever, specific dosage and duration not mentioned.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified, details on control treatment not available.
Number of subjects: 0
Study: 33808348

Group type: EXPERIMENTAL
Intervention: Standardized questionnaires assessing pain, quality of life, and catastrophizing.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Measurement of bone turnover biomarkers and inflammatory cytokines in fasting serum samples.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Evaluation of bone innervation in diagnostic biopsies.
Number of subjects: 0
Study: 33808371

Group type: EXPERIMENTAL
Intervention: Parental stress (measured using the Parental Stress Index)
Number of subjects: 250
Study: 33808883

Group type: COMPARATOR
Intervention: Total body adiposity indices (BMI, CUN-BAE, Deurenberg's formula) and abdominal adiposity (waist and neck circumferences, conicity index, waist to height ratio, Bonora's equation, A body shape index, body roundness index)
Number of subjects: 8188
Study: 33809385

Group type: EXPERIMENTAL
Intervention: NanoBEO (nanotechnology delivery system of bergamot essential oil deprived of furocumarins)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bergamot essential oil (BEO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 33809538

Group type: EXPERIMENTAL
Intervention: Luteinizing hormone (LH) and human chorionic gonadotropin (hCG)
Number of subjects: 591

Group type: EXPERIMENTAL
Intervention: sLHCGR
Number of subjects: 591
Study: 33809705

Group type: EXPERIMENTAL
Intervention: HIV+ and low iron stores (inflammation-unadjusted serum ferritin ≤ 40 µg/L)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 0
Study: 33810313

Group type: EXPERIMENTAL
Intervention: Eltrombopag
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Deferasirox
Number of subjects: 0

Group type: COMPARATOR
Intervention: Deferoxamine
Number of subjects: 0
Study: 33810795

Group type: EXPERIMENTAL
Intervention: Unicompartmental knee arthroplasty (UKA)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Total knee arthroplasty (TKA)
Number of subjects: 116
Study: 33811052

Group type: EXPERIMENTAL
Intervention: Prehabilitation intervention including a prehabilitation kit with an advice booklet and respiratory rehabilitation devices, monitored weekly for physical and respiratory rehabilitation, preoperative renutrition, motivational counselling, and iatrogenic prevention.
Number of subjects: 122
Study: 33811142

Group type: EXPERIMENTAL
Intervention: Anatomical imbalance mapping (AIM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Anatomical imbalance change
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Interindividual variation in whole-brain average anatomical imbalance
Number of subjects: 0
Study: 33811164

Group type: EXPERIMENTAL
Intervention: Routine skin cancer screening and education about skin self-exams (NCI cases)
Number of subjects: 293
Study: 33811182

Group type: EXPERIMENTAL
Intervention: High-definition ultrasound imaging before the brachial plexus block
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: High-definition ultrasound imaging after the brachial plexus block
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: High-definition ultrasound imaging at the lateral infraclavicular fossa after the brachial plexus block
Number of subjects: 100
Study: 33811291

Group type: EXPERIMENTAL
Intervention: 3D-Image guided RAPN (3D-IGRAPN)
Number of subjects: 157
Study: 33811356

Group type: EXPERIMENTAL
Intervention: Glecaprevir/Pibrentasvir (GLE/PIB)
Number of subjects: 80